The science
The symptoms are real. The mechanism is measurable.
Perimenopausal cognitive change has an evidence base. This page sets out the literature the formula draws on and the methodology our formulator applies to it.
What the literature shows
Summary of the cognitive-symptom evidence across the perimenopausal transition: what is consistently reported, what is measurable, and what remains under investigation.
Summary of the misattribution problem — how cognitive complaints are recoded as mood disorders at first presentation, and what the reported rates are.
Our formulator's methodology
01
Symptom mapping before supplementation
A structured intake that separates cognitive complaints — word retrieval, recall effort, sustained attention — from mood presentation, so the right thing is being treated.
02
Full clinical doses, never blend doses
Each botanical enters the formula at the dose used in the human trial data, rather than a fractional amount inside a proprietary blend.
03
Course length matched to onset windows
Assessment at 30 days, reassessment at 90. A shorter window produces a result that cannot be interpreted.
04
Batch verification before release
Third-party identity and potency testing on every batch, with the Certificate of Analysis available on request.
Referenced research
Learning — the expected gain from repeated cognitive testing — did not occur during the perimenopausal window, then resumed afterwards.
Verbal learning and memory performance was lowest in the early perimenopausal stage, independent of depressive symptoms and sleep complaints.
Roughly two-thirds of women report cognitive difficulties across the transition; objective testing shows modest, transient decrements concentrated in verbal memory and attention.
Serum cortisol fell significantly against placebo alongside reductions in standardised stress-scale scores over the 60-day course.
Both 250 mg and 600 mg daily doses reduced cortisol and perceived stress; the 600 mg arm showed the larger effect and improved sleep quality.
Standardised Rhodiola extract improved overall depression scores, with the clearest movement on emotional instability and somatic complaints.
Fatigue scores and attention performance improved against placebo, with a reduction in the morning cortisol response to awakening stress.
Steroidal saponins in Shatavari show consistent activity on reproductive and endocrine endpoints in preclinical models, with an emerging human evidence base.
Magnesium supplementation reduced stress scores; the combination with vitamin B6 produced the largest reduction in the severe-stress subgroup.
Low vitamin D status was associated with a significantly increased likelihood of depressive symptoms across cohort and case-control data.
References describe research on individual compounds and on the perimenopausal transition generally. They are not claims about this product.
The Formulator
San Francisco · Nutritionist and applied kinesiologist with almost 40 years of clinical practice, specialising in hormonal health and the perimenopausal transition.